Royal Caribbean dropped 6.1% on Tuesday and is down nearly 20% over the past month — yet options traders just turned the most bullish they have been all year.
The sharpest story this week is the divergence between the options market and the tape. The put/call ratio collapsed to 0.92 — nearly three standard deviations below its 20-day mean of 1.28. That z-score of -2.75 is the most extreme bullish options reading in at least 52 weeks, against a full-year low of 0.61. As recently as September 14, the PCR sat above 1.31. The rotation from hedging to call-buying accelerated precisely as the stock fell through $235, which is either opportunistic dip-buying or pre-earnings positioning ahead of the October 27 print. Both readings are plausible — but the speed of the move makes it hard to ignore.
The prior note from September 18 flagged an emerging tug-of-war between call buyers and short sellers. That tension has resolved, at least for now, in favor of the bulls — but with the stock lower. Short interest has actually pulled back slightly from the 3.9% peak reached on September 17, settling at 3.6% of free float (roughly 9.8 million shares). The week-on-week change is essentially flat at -0.3%. More tellingly, the borrow market remains completely unencumbered: availability stands near 1,990% — about 20 shares available for every one currently on loan — and cost to borrow is 0.53%, barely above the risk-free rate. There is no friction driving this PCR move. It is discretionary call buying into a falling stock.
The Street remains broadly constructive, though the gap between targets and current price has widened sharply. The analyst consensus mean sits at $347.60, implying roughly 48% upside from Tuesday's close of $234.89. BMO Capital reiterated Outperform with a $370 target this week. Most of the post-Q2 target revisions were upward — Wells Fargo, Citigroup, Stifel, and Susquehanna all lifted targets in late July after what appears to have been a strong earnings print (the stock moved +6.1% the day of results and +6.8% over the following five days). Morgan Stanley sits at Equal-Weight with a $300 target, the most cautious active voice on the name. The valuation has compressed hard: the P/E multiple is now near 11.9x and EV/EBITDA at 10.2x, both down meaningfully over the past 30 days. That repricing makes the relative bull case easier to frame, even as macro fears weigh on the travel sector broadly.
Peer moves this week add some context. VIK shed 5.8% on Tuesday and is off 4.7% on the week — a comparable drawdown to RCL's -5.8% weekly move — while PRKS and HGV both dropped over 6% on the week. CCL and NCLH held up far better, roughly flat on the week. The divergence within leisure suggests some stock-specific pressure on RCL beyond the broader sector move, though the catalyst is not apparent in this data.
The dominant institutional holder remains Capital Research entities — Capital Research Global Investors recently filed a 13G/A lifting their stake to 12.8% from 10.5%, a meaningful addition. All large holders are passive 13G filers; no activist 13D is on the register. The sole material insider action over the past 90 days was an open-market sale by the CEO of Royal Caribbean International, Michael Bayley, who sold 12,811 shares at roughly $316 on July 29 for $4.0 million — not under a 10b5-1 plan. That transaction was at a price nearly $80 above where the stock trades today.
With the Q3 earnings date confirmed for October 27, the setup heading into that print is what to watch: whether the recent call-buying reflects genuine conviction at these levels, or simply opportunistic trading in a stock that has compressed 20% in a month with no obvious fundamental break.
See the live data behind this article on ORTEX.
Open RCL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
